Literature DB >> 14597743

Radiotherapy patterns of care study in lung carcinoma.

B Movsas1, J Moughan, R Komaki, H Choy, R Byhardt, C Langer, M Goldberg, M Graham, D Ettinger, D Johnstone, R Abrams, R Munden, G Starkschall, J Owen.   

Abstract

PURPOSE: For the first time, a lung Patterns of Care Study was conducted to determine the national patterns of radiation (RT) practice in patients treated for nonmetastatic lung cancer in 1998 to 1999.
MATERIALS AND METHODS: A national survey of randomly selected RT institutions in the United States was conducted using two-stage cluster sampling, stratified by practice type. Patients with nonmetastatic lung cancer (Karnofsky performance score [KPS] > or = 60), who received RT as definitive or adjuvant therapy, were randomly selected. To determine national estimates, sample size was weighted by the relative number of institutions per strata and the number of patient records reviewed per the number of patients eligible. Accordingly, 42,335 patient records from 58 institutions were reviewed by trained research associates. The unweighted sample size (or number of patients) was 541.
RESULTS: The histologies were small-cell lung cancer (SCLC) in 14.5% of patients versus non-small-cell lung cancer (NSCLC) in 85.5% of patients. The median age was 67 years (range, 29 to 92 years); 61% of patients were male, and 38% were current smokers. Bone scans and brain imaging were not obtained in 34% and 52% of clinical stage (CS) III NSCLC patients, respectively. Regarding treatment strategies, for SCLC and CS III NSCLC, chemotherapy plus RT was used significantly more than RT alone (P <.05); in CS I NSCLC, RT alone was the primary treatment (P <.05). Overall, 58% of patients received systemic therapy. On multivariate analysis, factors correlating with increased use of chemotherapy included younger age, histology (SCLC > NSCLC), increasing CS, increasing KPS, and lack of comorbidities. Only 3% of all patients were treated on prospective clinical trials.
CONCLUSION: This study establishes the general patterns of care for lung carcinoma in RT facilities within the United States. As supported by clinical trials, patients with limited-stage SCLC and CS III NSCLC received chemotherapy plus RT more than they received RT alone. Further improvements in staging, smoking cessation, and increased accrual to clinical trials must be encouraged.

Entities:  

Mesh:

Year:  2003        PMID: 14597743     DOI: 10.1200/JCO.2003.04.018

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

Review 1.  Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms.

Authors:  Thomas E Stinchcombe; Elizabeth M Gore
Journal:  Oncologist       Date:  2010-02-09

2.  Once Daily High-dose Radiation (≥60 Gy) Treatment in Limited Stage Small Cell Lung Cancer.

Authors:  Amir Zahra; Tangel Chang; Taher Abu Hejleh; Muhammad Furqan; Gerald H Clamon; Sudershan K Bhatia; John M Watkins; Sarah L Mott; Logan L Ahmann; Kellie L Bodeker; Douglas R Spitz; John M Buatti; Bryan G Allen
Journal:  J Oncol Transl Res       Date:  2016-07-26

3.  Chemoradiotherapy duration correlates with overall survival in limited disease SCLC patients with poor initial performance status who successfully completed multimodality treatment.

Authors:  F Manapov; S Klöcking; M Niyazi; C Belka; G Hildebrandt; R Fietkau; G Klautke
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

Review 4.  Treatment of limited disease small cell lung cancer: the multidisciplinary team.

Authors:  Markus Glatzer; Achim Rittmeyer; Joachim Müller; Isabelle Opitz; Alexandros Papachristofilou; Ioannis Psallidas; Martin Früh; Diana Born; Paul Martin Putora
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

5.  Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey.

Authors:  Ritsuko Komaki; Najma Khalid; Corey J Langer; Feng-Ming Spring Kong; Jean B Owen; Cheryl L Crozier; J Frank Wilson; Xiong Wei; Benjamin Movsas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-27       Impact factor: 7.038

6.  Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.

Authors:  Joseph K Salama; Herbert Pang; Jeffrey A Bogart; A William Blackstock; James J Urbanic; Lydia Hogson; Jeffrey Crawford; Everett E Vokes
Journal:  Lung Cancer       Date:  2013-12       Impact factor: 5.705

Review 7.  The role of radiation therapy in small cell lung cancer.

Authors:  Gregory M M Videtic
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

8.  A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.

Authors:  Joseph K Salama; Lydia Hodgson; Herbert Pang; James J Urbanic; A William Blackstock; Steven E Schild; Jeffrey Crawford; Jeffrey A Bogart; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

9.  The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.

Authors:  Yaacov Richard Lawrence; Rebecca Paulus; Corey Langer; Maria Werner-Wasik; Mark K Buyyounouski; Ritsuko Komaki; Mitchell Machtay; Colum Smith; Rita S Axelrod; Todd Wasserman; Jeffrey D Bradley; Benjamin Movsas
Journal:  Lung Cancer       Date:  2013-03-07       Impact factor: 5.705

10.  Treatment recommendations for locally advanced, non-small-cell lung cancer: the influence of physician and patient factors.

Authors:  Irwin H Lee; James A Hayman; Mary Beth Landrum; Joel Tepper; May Lin Tao; Karyn A Goodman; Nancy L Keating
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-04       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.